Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2011 1
2013 1
2014 4
2015 9
2016 11
2017 2
2018 4
2019 4
2020 3
2021 8
2022 5
2023 4
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean m nejat (30 results)?
DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.
Vekariya U, Toma M, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszywalow-Bartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, Jelinek J, Sliwinski T, Ghosh J, Matlawska-Wasowska K, Chandramouly G, Nejati R, Wasik M, Sykes SM, Piwocka K, Hadzijusufovic E, Valent P, Pomerantz RT, Morton G, Childers W, Zhao H, Paietta EM, Levine RL, Tallman MS, Fernandez HF, Litzow MR, Gupta GP, Masson JY, Skorski T. Vekariya U, et al. Blood. 2023 May 11;141(19):2372-2389. doi: 10.1182/blood.2022018428. Blood. 2023. PMID: 36580665 Free PMC article.
Attentional network changes in subjective cognitive decline.
Esmaeili M, Nejati V, Shati M, Vatan RF, Chehrehnegar N, Foroughan M. Esmaeili M, et al. Aging Clin Exp Res. 2022 Apr;34(4):847-855. doi: 10.1007/s40520-021-02005-8. Epub 2021 Oct 27. Aging Clin Exp Res. 2022. PMID: 34705251
Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease.
Cummings J, Cohen S, Murphy J, Brothers HM, Nejati M, Forrestal F, de Moor C, O'Gorman J, Harrison J, Jaeger J, Mummery CJ, Porsteinsson AP, Potashman M, Tian Y, Yang L, He P, Haeberlein SB. Cummings J, et al. Alzheimers Dement. 2025 Jun;21(6):e70224. doi: 10.1002/alz.70224. Alzheimers Dement. 2025. PMID: 40545559 Free PMC article. Clinical Trial.
52 results